.jpeg)
When will Ripretinib be included in medical insurance?
Ripretinib The original drug has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is only available to patients who meet the indications. Adult patients with advanced gastrointestinal stromal tumor (GIST) who have received three or more kinase inhibitors (including imatinib) in the past and are not eligible can only purchase it at their own expense. The reimbursement ratio is different in different regions, and the price after reimbursement may be different. Gastrointestinal stromal tumor is a tumor originating from the gastrointestinal tract. The recommended dose is 150 mg once a day. The price of each box of 50 mg*30 tablets may be around 30,000 yuan.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
